Research Summary

I am a medical oncologist with a PhD in cell and molecular biology. I maintain an active academic clinical practice and lead a basic and translational research laboratory focused on cancer genetics, precision medicine, and the molecular basis of targeted therapy response and resistance. I have discovered several mechanisms of resistance to EGFR-targeted therapy, BRAF- and MEK-targeted therapy, and ALK-targeted therapy in lung and other cancers. I direct a multi-disciplinary team engaged in laboratory-based patient-focused research, and I am an investigator on clinical trials, including rational upfront polytherapy trials designed to forestall and eliminate resistance and that are motivated by my laboratory-based discoveries.

Research Funding

  • July 1, 2021 - June 30, 2026 - UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: K12CA260225
  • July 1, 2019 - June 30, 2024 - (PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA231300
  • February 1, 2013 - January 31, 2024 - Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA169338
  • September 30, 2017 - August 31, 2022 - Bay Area Team Against Resistance , Principal Investigator . Sponsor: NIH, Sponsor Award ID: U54CA224081

Education

Vanderbilt University, B.S., 1998, Molecular Biology
New York University, School of Medicine, Ph.D., 2004, Cell and Mol. Biology
New York University, School of Medicine, M.D., 2005, Medicine
Brigham and Women’s Hospital/Harvard, 2005-2007, Internal Medicine
Memorial Sloan-Kettering Cancer Center, 2007-2011, Medical Oncology

Honors & Awards

  • 1998
    Vanderbilt University Honors Degree in Molecular Biology
  • 1998
    Vanderbilt University Research Excellence Award
  • 1998-2005
    NIH Medical Scientist Training Program Award
  • 2005
    Medical Science Writing Award, NYU School of Medicine
  • 2007
    US Patent 20060083742 Prenyl-electrostatic Switch
  • 2008-2010
    Charles A. Dana Foundation Clinical Scholars Research Fellowship
  • 2009
    Julia Zelmanovich Young Alumnus Award, NYU School of Medicine
  • 2010
    American Society of Clinical Oncology Young Investigator Award
  • 2010
    Uniting Against Lung Cancer Research Investigator
  • 2011
    NIH/NCI Clinical Investigator Career Development Award (K08)
  • 2012
    National Lung Cancer Partnership Young Investigator Award
  • 2012
    Sidney Kimmel Foundation Kimmel Scholar Award
  • 2012
    Damon Runyon Clinical Investigator Award Finalist
  • 2012
    Doris Duke Clinical Scientist Development Award
  • 2012
    American Lung Association Lung Cancer Discovery Award
  • 2012
    Doris Duke Charitable Foundation Clinical Scientist Development Award
  • 2012
    Visiting Scholar Howard Hughes Medical Institute (HHMI) Scholars Program at California, State University-Fullerton
  • 2012
    NIH Director's New Innovator Award (DP2)
  • 2013
    Searle Scholar Award
  • 2014
    Lung Cancer Innovators Award (Addario and Van Auken Foundations)
  • 2015
    Pew-Stewart Scholar, Pew Charitable Trust

Selected Publications

  1. Noronha A, Belugali Nataraj N, Sang Lee J, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr DL, Wu W, Sekar A, Giri S, Chung Y, Drago-Garcia D, Danysh BP, Lauriola M, Fiorentino M, Ardizzoni A, Oren M, Blakely CM, Ezike J, Wiemann S, Parida L, Bivona TG, Aqeilan RI, Brugge JS, Regev A, Getz G, Ruppin E, Yarden Y. AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer. Cancer Discov. 2022 Jul 27.  View on PubMed
  2. Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, Rotow J, Mayekar MK, Haderk F, Chatterjee N, Urisman A, Yeo JC, Skanderup AJ, Tan AC, Tam WL, Arrieta O, Hosomichi K, Nishiyama A, Yano S, Kirichok Y, Tan DS, Rosell R, Okimoto RA, Bivona TG. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. J Clin Invest. 2022 07 01; 132(13).  View on PubMed
  3. Yang D, Jones MG, Naranjo S, Rideout WM, Min KHJ, Ho R, Wu W, Replogle JM, Page JL, Quinn JJ, Horns F, Qiu X, Chen MZ, Freed-Pastor WA, McGinnis CS, Patterson DM, Gartner ZJ, Chow ED, Bivona TG, Chan MM, Yosef N, Jacks T, Weissman JS. Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell. 2022 05 26; 185(11):1905-1923.e25.  View on PubMed
  4. Tyner JW, Haderk F, Kumaraswamy A, Baughn LB, Van Ness B, Liu S, Marathe H, Alumkal JJ, Bivona TG, Chan KS, Druker BJ, Hutson AD, Nelson PS, Sawyers CL, Willey CD. Understanding Drug Sensitivity and Tackling Resistance in Cancer. Cancer Res. 2022 04 15; 82(8):1448-1460.  View on PubMed
  5. Ali M, Lu M, Ang HX, Soderquist RS, Eyler CE, Hutchinson HM, Glass C, Bassil CF, Lopez OM, Kerr DL, Falcon CJ, Yu HA, Hata AN, Blakely CM, McCoach CE, Bivona TG, Wood KC. Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Sci Transl Med. 2022 03 30; 14(638):eabc7480.  View on PubMed
  6. Manabe T, Bivona TG. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer. J Clin Invest. 2022 02 15; 132(4).  View on PubMed
  7. Pedraz-Valdunciel C, Giannoukakos S, Potie N, Giménez-Capitán A, Huang CY, Hackenberg M, Fernandez-Hilario A, Bracht J, Filipska M, Aldeguer E, Rodríguez S, Bivona TG, Warren S, Aguado C, Ito M, Aguilar-Hernández A, Molina-Vila MA, Rosell R. Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens. Mol Oncol. 2022 06; 16(12):2367-2383.  View on PubMed
  8. Gui P, Bivona TG. Evolution of metastasis: new tools and insights. Trends Cancer. 2022 02; 8(2):98-109.  View on PubMed
  9. Barbosa Rabago D, Blakely CM, Haderk F, Bivona TG. Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids. J Vis Exp. 2021 11 22; (177).  View on PubMed
  10. Wu Q, Luo X, Terp MG, Li Q, Li Y, Shen L, Chen Y, Jacobsen K, Bivona TG, Chen H, Zeng R, Ditzel HJ. DDX56 modulates post-transcriptional Wnt signaling through miRNAs and is associated with early recurrence in squamous cell lung carcinoma. Mol Cancer. 2021 08 26; 20(1):108.  View on PubMed
  11. Zaman A, Bivona TG. Targeting AXL in NSCLC. Lung Cancer (Auckl). 2021; 12:67-79.  View on PubMed
  12. Zaman A, Wu X, Lemoff A, Yadavalli S, Lee J, Wang C, Cooper J, McMillan EA, Yeaman C, Mirzaei H, White MA, Bivona TG. Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer. Cell Rep. 2021 08 03; 36(5):109491.  View on PubMed
  13. Chou YT, Bivona TG. Inhibition of SHP2 as an approach to block RAS-driven cancers. Adv Cancer Res. 2022; 153:205-236.  View on PubMed
  14. Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, Leighl N, Malapelle U, Mok T, Peled N, Raez LE, Sequist L, Sholl L, Swanton C, Abbosh C, Tan D, Wakelee H, Wistuba I, Bunn R, Freeman-Daily J, Wynes M, Belani C, Mitsudomi T, Gandara D. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021 10; 16(10):1647-1662.  View on PubMed
  15. Gui P, Bivona TG. Stepwise evolution of therapy resistance in AML. Cancer Cell. 2021 07 12; 39(7):904-906.  View on PubMed
  16. Tulpule A, Guan J, Neel DS, Allegakoen HR, Lin YP, Brown D, Chou YT, Heslin A, Chatterjee N, Perati S, Menon S, Nguyen TA, Debnath J, Ramirez AD, Shi X, Yang B, Feng S, Makhija S, Huang B, Bivona TG. Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Cell. 2021 05 13; 184(10):2649-2664.e18.  View on PubMed
  17. Quinn JJ, Jones MG, Okimoto RA, Nanjo S, Chan MM, Yosef N, Bivona TG, Weissman JS. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science. 2021 02 26; 371(6532).  View on PubMed
  18. Kerr DL, Haderk F, Bivona TG. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. Curr Opin Chem Biol. 2021 06; 62:1-12.  View on PubMed
  19. Nothdurft S, Thumser-Henner C, Breitenbücher F, Okimoto RA, Dorsch M, Opitz CA, Sadik A, Esser C, Hölzel M, Asthana S, Forster J, Beisser D, Kalmbach S, Grüner BM, Bivona TG, Schramm A, Schuler M. Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. Oncogenesis. 2020 Nov 19; 9(11):102.  View on PubMed
  20. Liu J, Mayekar MK, Wu W, Yan M, Guan H, Wang J, Zaman A, Cui Y, Bivona TG, Choudhry H, Xing Q, Cao W. Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G. Cancer Lett. 2020 11 28; 493:217-227.  View on PubMed

Go to UCSF Profiles, powered by CTSI